Novo Nordisk gears up for Ozempic launch in India, sources say | REUTERS

Key Concepts

• Ampic (Semaglutide): Novo Nordisk's blockbuster diabetes drug, also used off-label for weight loss.
• WGOI (Semaglutide): Novo Nordisk's drug approved for weight loss.
• Ozempic: Novo Nordisk's brand name for semaglutide in India.
• Mounjaro: Eli Lilly's competing drug for diabetes and weight loss.
• Type 2 Diabetes: A chronic condition characterized by high blood sugar levels.
• Obesity: A complex disease involving an excessive amount of body fat.
• Weight Loss Treatment Market: The rapidly growing market for drugs and therapies aimed at reducing body weight.
• Off-label Use: Prescribing a drug for a condition or in a dosage not officially approved by regulatory bodies.
• Indian Regulatory Approval: The process by which drugs are authorized for sale and use in India.

Novo Nordisk's Launch of Ampic in India

Novo Nordisk is set to launch its highly successful diabetes drug, Ampic, in India this month, according to three sources with knowledge of the matter. This strategic move aims to bolster the Danish pharmaceutical company's presence in the Indian market.

Rationale for Market Entry

India presents a significant opportunity for Novo Nordisk due to its large population, ranking second globally in the number of individuals with type 2 diabetes, trailing only China. Furthermore, the country is experiencing escalating rates of obesity. These factors combine to make India a crucial battleground for pharmaceutical companies vying for a share of the rapidly expanding weight loss treatment market. Analysts project this market to reach a value of $150 billion annually by the end of the current decade.

Ampic: A Blockbuster Drug

Ampic, a once-weekly injectable medication, has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. Globally, it is a bestseller and is frequently used off-label for weight loss due to its efficacy in suppressing appetite.

Novo Nordisk's Other Weight Loss Medication

Novo Nordisk also has another semaglutide-based drug, WGOI, which is specifically approved for weight loss. In September, the company announced that it had secured regulatory approval from Indian authorities to import and market this drug. On Thursday, Novo Nordisk expressed its intention to launch the drug as soon as possible, though specific details regarding an updated timeline and pricing were not provided.

Competitive Landscape

This launch occurs amidst intense competition from U.S. rival Eli Lilly. Eli Lilly's drug, Mounjaro, is approved for both diabetes and weight loss. Data indicates that Mounjaro became India's top-selling drug by value in October, highlighting the competitive nature of the market.

Conclusion

Novo Nordisk's impending launch of Ampic in India signifies a strategic push into a high-growth market driven by the prevalence of type 2 diabetes and rising obesity rates. The company aims to leverage the success of its semaglutide-based medications in a market projected for substantial expansion, while facing strong competition from established players like Eli Lilly.